title: Chronic myeloid leukemia patients call for quality and consistency when generics are introduced to treat their cancer.
authors.affiliation: Leukemia Patient Advocates Foundation, Bern, Switzerland.|LeukaNET e.V., Riemerling, Germany.
authors.forename: J
authors.initials: J
authors.lastname: Geissler
authors.affiliation: Leukemia Patient Advocates Foundation, Bern, Switzerland.|Israeli CML Patients Organization, Netanya, Israel.
authors.forename: G
authors.initials: G
authors.lastname: Sharf
authors.affiliation: CML Association of Serbia, Belgrade, Serbia.
authors.forename: J
authors.initials: J
authors.lastname: Cugurovic
authors.affiliation: Touched by Max, Navotas City, The Philippines.
authors.forename: R
authors.initials: R
authors.lastname: Padua
authors.affiliation: Lithuanian Cancer Patient Coalition, Kaunas, Lithuania.
authors.forename: Š
authors.initials: Š
authors.lastname: Narbutas
authors.affiliation: Slovenian Lymphoma and Leukemia Patient Association, Ljubljana, Slovenia.
authors.forename: M
authors.initials: M
authors.lastname: Remic
authors.affiliation: Friends of Max, Mumbai, India.
authors.forename: V
authors.initials: V
authors.lastname: Venkatesh
mesh_terms: D000970:Antineoplastic Agents / Q000592:standards / Q000627:therapeutic use*; D004345:Drug Industry; D016568:Drugs, Generic / Q000592:standards / Q000627:therapeutic use*; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D011786:Quality Control
chemical_list: D000970:Antineoplastic Agents; D016568:Drugs, Generic; D000068877:Imatinib Mesylate